- Home
- ANNX vs INV Comparison
ANNX vs INV Comparison
Compare ANNX & INV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- INV
- Stock Information
- Founded
- ANNX 2011
- INV 2015
- Country
- ANNX United States
- INV United States
- Employees
- ANNX N/A
- INV N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- INV
- Sector
- ANNX Health Care
- INV
- Exchange
- ANNX Nasdaq
- INV NYSE
- Market Cap
- ANNX 553.2M
- INV 662.9M
- IPO Year
- ANNX 2020
- INV N/A
- Fundamental
- Price
- ANNX $4.20
- INV $12.60
- Analyst Decision
- ANNX Strong Buy
- INV
- Analyst Count
- ANNX 7
- INV 0
- Target Price
- ANNX $15.80
- INV N/A
- AVG Volume (30 Days)
- ANNX 1.5M
- INV 139.6K
- Earning Date
- ANNX 11-14-2024
- INV 02-15-2025
- Dividend Yield
- ANNX N/A
- INV N/A
- EPS Growth
- ANNX N/A
- INV N/A
- EPS
- ANNX N/A
- INV N/A
- Revenue
- ANNX N/A
- INV $988,000.00
- Revenue This Year
- ANNX N/A
- INV N/A
- Revenue Next Year
- ANNX N/A
- INV N/A
- P/E Ratio
- ANNX N/A
- INV N/A
- Revenue Growth
- ANNX N/A
- INV 4.88
- 52 Week Low
- ANNX $3.86
- INV $8.55
- 52 Week High
- ANNX $8.40
- INV $18.75
- Technical
- Relative Strength Index (RSI)
- ANNX 31.21
- INV N/A
- Support Level
- ANNX $4.53
- INV N/A
- Resistance Level
- ANNX $4.99
- INV N/A
- Average True Range (ATR)
- ANNX 0.31
- INV 0.00
- MACD
- ANNX -0.08
- INV 0.00
- Stochastic Oscillator
- ANNX 14.07
- INV 0.00
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.